Close

Walter Reinisch, MD

Professor, Division of Gastroenterology, Department of Medicine

Chairholder, Audrey Campbell Chair in Ulcerative Colitis Research

Associate Professor, Gastroenterology, Division of Gastroenterology & Hepatology, Medical University of Vienna

Email: reinisw@mcmaster.ca

Dr. Reinisch, MD, graduated at the Medical University of Vienna (MUV), where he finished his training in Internal Medicine and Gastroenterology. After initial scientific studies in oncology at the MUV and the National Cancer Institute, Frederick, MD, he decided to focus his research interest on inflammatory Bowel disease (IBD). Dr. Reinisch is founding member of the European Crohn’s & Colitis Organisation (ECCO) and was assigned as honorary member after having contributed in various positions. He was active in the Scientific and Public Affairs Committee of the United European Gastroenterology (UEG) and headed the Austrian IBD Study Group. Dr. Reinisch is member of the International Organization For the Study of Inflammatory Bowel Disease (IOIBD).

Dr. Reinisch is an expert in designing, conducting and interpreting the results of clinical trials in IBD. He envisions a customized management of IBD utilizing the innovations of translational medicine. He advocates the implementation of a “common language of inflammatory bowel disease” to improve the communication with patients and between physicians for a better care and more robust research outcomes.

  1. GlobalSurg Collaborative. Laparoscopy in management of appendicitis in high-, middle-, and low-income countries: a multicenter, prospective, cohort study. Surg Endosc. 2018; :. doi: 10.1007/s00464-018-6064-9. PubMed PMID:29623470 .
  2. Schwarz, E, Reinisch, G, Brandauer, A, Aharinejad, S, Scharf, W, Trieb, K et al.. Load transfer and periprosthetic fractures after total hip arthoplasty: Comparison of periprosthetic fractures of femora implanted with cementless distal-load or proximal-load femoral components and measurement of the femoral strain at the time of implantation. Clin Biomech (Bristol, Avon). 2018;54 :137-142. doi: 10.1016/j.clinbiomech.2018.03.010. PubMed PMID:29587147 .
  3. Patuzzi, GC, Lira, APS, Santos, JDM, Reinisch, AOB, Veleda, AA. Academic learning about public health in a Canadian university: contributions for Brazilian education. Rev Gaucha Enferm. 2018;38 (3):e0012. doi: 10.1590/1983-1447.2017.03.2016-0012. PubMed PMID:29538605 .
  4. Ehrenkranz, PD, Calleja, JM, El-Sadr, W, Fakoya, AO, Ford, N, Grimsrud, A et al.. A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders. J Int AIDS Soc. 2018;21 (3):. doi: 10.1002/jia2.25080. PubMed PMID:29537628 PubMed Central PMC5851343.
  5. Miehsler, W, Dejaco, C, Gröchenig, HP, Fuchssteiner, H, Högenauer, C, Kazemi-Shirazi, L et al.. [Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases]. Z Gastroenterol. 2018;56 (3):275-302. doi: 10.1055/s-0044-100044. PubMed PMID:29529682 .
  6. Louis, EJ, Reinisch, W, Schwartz, DA, Löfberg, R, Robinson, AM, Berg, S et al.. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. Adv Ther. 2018; :. doi: 10.1007/s12325-018-0678-0. PubMed PMID:29516410 .
  7. Horenkamp, FA, Valverde, DP, Nunnari, J, Reinisch, KM. Molecular basis for sterol transport by StART-like lipid transfer domains. EMBO J. 2018;37 (6):. doi: 10.15252/embj.201798002. PubMed PMID:29467216 PubMed Central PMC5852651.
  8. GlobalSurg Collaborative. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study. Lancet Infect Dis. 2018; :. doi: 10.1016/S1473-3099(18)30101-4. PubMed PMID:29452941 .
  9. Rosario, M, French, JL, Dirks, NL, Sankoh, S, Parikh, A, Yang, H et al.. Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2018;12 (4):510. doi: 10.1093/ecco-jcc/jjx168. PubMed PMID:29385425 .
  10. Eser, A, Primas, C, Reinisch, S, Vogelsang, H, Novacek, G, Mould, DR et al.. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. J Clin Pharmacol. 2018; :. doi: 10.1002/jcph.1069. PubMed PMID:29381220 .
Search PubMed
Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn